{"id":"NCT02138136","sponsor":"Sucampo Pharma Americas, LLC","briefTitle":"Lubiprostone for Children With Constipation","officialTitle":"A Multicentre, Long-term Safety, Efficacy, and Pharmacokinetics Study of Lubiprostone in Paediatric Subjects Aged ≥ 6 Years to < 18 Years With Functional Constipation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-02-26","primaryCompletion":"2017-05-01","completion":"2017-05-01","firstPosted":"2014-05-14","resultsPosted":"2020-01-21","lastUpdate":"2020-01-21"},"enrollment":419,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Constipation - Functional"],"interventions":[{"type":"DRUG","name":"Lubiprostone","otherNames":["Amitiza®"]}],"arms":[{"label":"Lubiprostone","type":"EXPERIMENTAL"}],"summary":"This study is for children with constipation.\n\nChildren who completed 3 months of treatment in the earlier study (NCT02042183):\n\n* were invited to participate\n* will receive lubiprostone for 9 more months\n* will see if lubiprostone safely relieves their constipation if taken for a whole year","primaryOutcome":{"measure":"Median Number of Observed Weekly Spontaneous Bowel Movements (SBM) Per Month","timeFrame":"within 9 months","effectByArm":[{"arm":"All Participants","deltaMin":2.66,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":85,"countries":["United States","Belgium","Canada","France","Netherlands","Poland","United Kingdom"]},"refs":{"pmids":["33838349"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":419},"commonTop":["Vomiting","Nausea","Headache","Abdominal pain","Nasopharyngitis"]}}